Gritstone bio, Inc. Common Stock
GRTS
GRTS was delisted on the 21st of October, 2024.
43 hedge funds and large institutions have $194M invested in Gritstone bio, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 43 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CV
Clarus Ventures
Cambridge,
Massachusetts
|
+$36.6M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$31.9M |
| 3 |
FM
Frazier Management
Seattle,
Washington
|
+$29.4M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$23.5M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$15.2M |
Top Sellers
GRTS Hedge Fund Activity: Q3 2018 in Review
43 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Gritstone bio, Inc. Common Stock (GRTS) for Q3 2018, worth a combined $194M.
Buyers outnumbered sellers: 43 funds opened new GRTS positions and 0 closed out — a net gain of 43 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Clarus Ventures, opening a new position worth an estimated $36.6M.
- 43 institutional investors held Gritstone bio, Inc. Common Stock (GRTS) as of Q3 2018, up from 0 in Q2 2018.
- Funds reported $194M of Gritstone bio, Inc. Common Stock stock for Q3 2018.
- 43 funds opened new Gritstone bio, Inc. Common Stock positions in Q3 2018 and 0 closed out, a net change of +43 holders.
- The largest Gritstone bio, Inc. Common Stock buyer in Q3 2018 was Clarus Ventures, an estimated $36.6M added.
Based on aggregated 13F filings for Q3 2018.